Diversified Trust Co Sells 7,734 Shares of Amgen Inc. $AMGN

by · The Cerbat Gem

Diversified Trust Co lowered its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 19.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,615 shares of the medical research company’s stock after selling 7,734 shares during the period. Diversified Trust Co’s holdings in Amgen were worth $11,476,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. increased its stake in shares of Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after purchasing an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new position in shares of Amgen during the 4th quarter worth about $1,669,000. Adell Harriman & Carpenter Inc. boosted its stake in Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Amgen during the 4th quarter valued at approximately $22,441,000. Finally, Sigma Planning Corp grew its holdings in Amgen by 24.0% in the 4th quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock valued at $5,889,000 after buying an additional 3,488 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $337.60 on Friday. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a market cap of $182.21 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42. The business’s 50-day simple moving average is $340.71 and its 200 day simple moving average is $345.76.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the prior year, the firm posted $4.90 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent analyst reports. Argus dropped their price target on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, May 20th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Mizuho raised their price objective on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 16th. Royal Bank Of Canada boosted their target price on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Finally, Daiwa Securities Group dropped their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $354.42.

View Our Latest Stock Report on Amgen

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

See Also